City Therapeutics Aims for $158M IPO as Iambic Targets $135M

City Therapeutics has set its sights on raising $158 million in an initial public offering, according to Endpoints News, while Iambic Therapeutics is separately seeking $135 million in a Nasdaq debut of its own.

The two filings, reported by Endpoints News, put a combined $293 million of potential biotech capital formation in motion at a single stroke. Both companies have chosen Nasdaq as their listing venue, according to the report.

What do the two deals have in common?

Each company is pursuing a conventional IPO structure rather than an alternative route such as a SPAC merger or a direct listing. The reported target sizes — $158 million for City Therapeutics and $135 million for Iambic — place both deals in the mid-range of recent biotech flotations, large enough to attract institutional attention without demanding the outsized commitments that larger, later-stage issuers require.

Endpoints News, a trade publication covering drug development and biotech finance, reported both targets in a single dispatch, signaling that the two offerings are moving through the pipeline in parallel.

The shared Nasdaq destination reflects the exchange's long-standing dominance in biotech listings, where trading liquidity and analyst coverage concentrate around life-science issuers.

Why does the timing matter?

Two sizeable biotech IPOs arriving together test whether the new-issue window for drug developers remains open. IPO markets for biotech have cycled between feast and famine in recent years, and underwriters watch each new filing's reception as a signal for the next cohort of issuers.

A successful pricing for City Therapeutics at or near its $158 million target would mark one of the larger biotech debuts of the current cycle. The same holds for Iambic at $135 million. Conversely, a cut in size or postponed pricing would give later-stage private companies a reason to delay their own listing plans.

What happens next?

The next concrete milestones are pricing and the first day of trading for each deal, when the market will render its verdict on both the reported valuations and the broader appetite for biotech risk. Should both companies complete their offerings at target, expect other venture-backed developers to follow with filings of their own.